Vegf antagonist formulations suitable for intravitreal administration
US-2025257118-A1 · Aug 14, 2025 · US
This page is not indexed by search engines while we improve data quality.
Furfine Eric patents
Furfine Eric is listed as an inventor on 30 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Furfine Eric |
| Total patents | 30 |
| First publication | Mar 3, 2015 |
| Latest publication | Aug 14, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
VEGF antagonist formulations suitable for intravitreal administration
US-12331099-B2 · Jun 17, 2025 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2025042972-A1 · Feb 6, 2025 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2023374108-A1 · Nov 23, 2023 · US
VEGF antagonist formulations suitable for intravitreal administration
US-11732024-B2 · Aug 22, 2023 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2021340220-A1 · Nov 4, 2021 · US
VEGF antagonist formulations suitable for intravitreal administration
US-11084865-B2 · Aug 10, 2021 · US
VEGF antagonist formulations suitable for intravitreal administration
US-11066458-B2 · Jul 20, 2021 · US
Serum albumin binding molecules
US-10934572-B2 · Mar 2, 2021 · US
Multivalent fibronectin based scaffold domain proteins
US-2021017252-A1 · Jan 21, 2021 · US
Recent patents
Latest publications not already listed above.
Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
US-10774130-B2 · Sep 15, 2020 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2020131246-A1 · Apr 30, 2020 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2020017572-A1 · Jan 16, 2020 · US
VEGF antagonist formulations suitable for intravitreal administration
US-10464992-B2 · Nov 5, 2019 · US
VEGF antagonist formulations suitable for intravitreal administration
US-10400025-B2 · Sep 3, 2019 · US
Serum albumin binding molecules
US-2019203248-A1 · Jul 4, 2019 · US
Serum albumin binding molecules
US-10221438-B2 · Mar 5, 2019 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2019031735-A1 · Jan 31, 2019 · US
Multivalent fibronectin based scaffold domain proteins
US-2018265572-A1 · Sep 20, 2018 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2018155408-A1 · Jun 7, 2018 · US
VEGF antagonist formulations suitable for intravitreal administration
US-9914763-B2 · Mar 13, 2018 · US
Multivalent fibronectin based scaffold domain proteins
US-9902762-B2 · Feb 27, 2018 · US
Serum albumin binding molecules
US-2017145464-A1 · May 25, 2017 · US
VEGF antagonist formulations suitable for intravitreal administration
US-9580489-B2 · Feb 28, 2017 · US
Serum albumin binding molecules
US-9540424-B2 · Jan 10, 2017 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2016244505-A1 · Aug 25, 2016 · US
Vegf antagonist formulations suitable for intravitreal administration
US-2016213608-A1 · Jul 28, 2016 · US
VEGF antagonist formulations for intravitreal administration
US-9340594-B2 · May 17, 2016 · US
Serum albumin binding molecules
US-2015152147-A1 · Jun 4, 2015 · US
Serum albumin binding molecules
US-8969289-B2 · Mar 3, 2015 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Regeneron Pharma | 19 |
| Bristol Myers Squibb Co | 11 |
| Gosselin Michael L | 1 |
| Fabrizio David | 1 |
| Swain Joanna F | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P43/00 | 26 |
| C07K2319/00 | 23 |
| A61P35/00 | 23 |
| C07K14/71 | 23 |
| A61K47/10 | 19 |